Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adam Wellikoff

Pulmonary Disease Atlantis, FL Medical Doctor

NPI 1407013527 CMS profile 244488

5401 S Congress Ave, Ste 204, Atlantis, FL 33462

Open in the dashboard

General payments

$18,763

530 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam Wellikoff of Atlantis, FL is reported in the CMS Open Payments database as having received $18,763 across 530 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,824 113
2024 General $9,534 111
2023 General $2,154 124
2022 General $1,286 71
2021 General $912 48
2020 General $476 35
2019 General $1,577 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Wellikoff
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Adam Wellikoff were reported at $2,824. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Adam Wellikoff Pulmonary Disease median Middle half National median
2019 $1,577 $377 $109–$1,340 $163
2020 $476 $230 $56–$907 $114
2021 $912 $269 $68–$1,072 $132
2022 $1,286 $390 $100–$1,457 $149
2023 $2,154 $419 $114–$1,659 $160
2024 $9,534 $476 $123–$1,818 $164
2025 $2,824 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $6,675 11 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $1,304 56 payments
  3. AstraZeneca Pharmaceuticals LP $1,282 64 payments
  4. Pulmonx Corporation $1,279 11 payments
  5. GlaxoSmithKline, LLC. $1,273 84 payments
  6. Inogen, Inc. $1,034 84 payments
  7. ANI Pharmaceuticals, Inc. $829 17 payments
  8. Grifols USA, LLC $732 48 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $579 22 payments
  10. Regeneron Healthcare Solutions, Inc. $428 14 payments
  11. Other $3,348 119 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,760 509 payments
  2. Education $6,021 12 payments
  3. Travel and Lodging $1,982 9 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $6,675 11 payments
  2. Pulmonx Endobronchial Valve EBV $1,197 8 payments
  3. OFEV $1,056 45 payments
  4. INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH $846 66 payments
  5. PURIFIED CORTROPHIN GEL $774 15 payments
  6. TRELEGY ELLIPTA $709 42 payments
  7. Prolastin-C Liquid $681 44 payments
  8. GLASSIA $579 22 payments
  9. DUPIXENT $550 14 payments
  10. FASENRA $515 23 payments
  11. Other $6,692 304 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

2,681

Median for Pulmonary Disease: 936

Drug cost

$2,432,993

Median for Pulmonary Disease: $487,987

Branded share of claims

72.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 94 $1,183,607
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 510 $532,954
Prolastin C Alpha-1-Proteinase Inhibitor Brand 12 $118,468
Nucala Mepolizumab Brand 26 $96,791
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 107 $92,820
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 146 $89,702
Spiriva Respimat Tiotropium Bromide Brand 90 $73,636
Breo Ellipta Fluticasone/Vilanterol Brand 108 $64,535
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 109 $60,627
Bevespi Aerosphere Glycopyrrolate/Formoterol Fum Brand 34 $21,251

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$180,037

Medicare's payments for the services billed

Medicare patients

707

Average age 76

Services billed

2,340

369 women, 338 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 66%
Ischemic heart disease 57%
Arthritis 53%
Heart failure 49%
Diabetes 47%
Chronic kidney disease 44%
Atrial fibrillation 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $680
$680 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $198
  • GENZYME CORPORATION $142
  • SANOFI-AVENTIS U.S. LLC $100
$439 — —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $192
$192 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $171
$171 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $136
$136 94 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

530 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record